J Bone Metab.
2024 Nov;31(4):264-278. 10.11005/jbm.24.789.
Clinical Utility of Bone Turnover Markers in Chronic Kidney Disease
- Srisuwarn P
1,2 - Eastell R1
- Salam S1,3
- Affiliations
-
- 1Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK
- 2Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
- 3Metabolic Bone Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
- KMID: 2561863
- DOI: http://doi.org/10.11005/jbm.24.789
Abstract
- Chronic kidney disease (CKD) often leads to mineral and bone disorders (CKD-MBDs), which are nearly universal in patients undergoing dialysis. CKD-MBD includes abnormal calcium-phosphate metabolism, vascular and soft tissue calcification, and bone abnormalities (renal osteodystrophy [ROD]). Bone fragility in CKD occurs due to low bone mass and poor bone quality, and patients with CKD have higher fracture and mortality rates. Bone histomorphometry is the gold standard for ROD diagnosis; however, it is labor-intensive and expensive. The Kidney Disease Improving Global Outcomes clinical practice guidelines on CKD-MBD suggest serum parathyroid hormone (PTH) and bone-specific alkaline phosphatase (bone ALP) for predicting bone turnover in ROD. In this review, we focus on the role of PTH and bone turnover markers, intact procollagen type N-terminal propeptide of type I collagen, bone ALP, and tartrate-resistant acid phosphatase 5b in diagnosing ROD, predicting fractures, and guiding treatment in patients with CKD.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Osteoporosis in Patients with Chronic Kidney Disease
- Changes of Biochemical Markers of Bone turnover in Pre-, Peri-and Postmenopausal Women
- A Case Report of High-turnover Renal Osteodystrophy with Positive Aluminum Staining
- Biochemical Markers of Bone Turnover
- Clinical Utility of Biological Markers of Bone Turnover in Children and Adolescents
